Premium
Treatment of acute monoblastic leukaemia by combination of recombinant human macrophage colony‐stimulating factor and low dose of ara‐C
Author(s) -
Kitano Kiyoshi,
Kobayashi Hikaru,
Maeyama Hironobu,
Miyabayashi Hidegaru,
Furuta Seiichi
Publication year - 1993
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1993.tb08663.x
Subject(s) - medicine , cytarabine , refractory (planetary science) , macrophage colony stimulating factor , recombinant dna , colony stimulating factor , macrophage , immunology , cytosine , gastroenterology , chemotherapy , biology , haematopoiesis , stem cell , in vitro , biochemistry , genetics , dna , astrobiology , gene
Summary. We present a patient with acute monoblastic leukaemia (AMoL) who achieved a complete remission on combination therapy with macrophage colony‐stimulating factor (M‐CSF) and low dose of cytosine arabinoside (ara‐C). This 26‐year‐old man was admitted with a relapse of AMoL which proved refractory to several chemotherapeutic regimens. To kill dormant leukaemic cells, we administered 20 mg/m ara‐C by continuous intravenous infusion and 800 × 10 4 unit M‐CSF by 30 min drip intravenous infusion together for 14 d. The blasts disappeared, followed by a recovery of normal blood cells. The patient continued the complete remission for 5 months. This observation suggests that a combination M‐CSF and a low dose of ara‐C may be useful in treating some patients with AMoL.